NWRN News

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia (TRS).

August 12, 2025Clinical Trials

Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction

NWRN

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--New findings in Neuropsychopharmacology - first to demonstrate that evenamide targets the key site of schizophrenia pathology in the hippocampus.

August 11, 2025Clinical Trials